Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23950486 | 0.92 | NLRP3 (0.42) | NLRP3TP53POLBRXFP1KDM4E | |
| SCHEMBL23950488 | 0.87 | NLRP3 (0.45) | NLRP3PDE4BPOLBGPR139MAPT | |
| SCHEMBL23950798 | 0.78 | NLRP3 (0.38) | NLRP3TP53POLBRXFP1KDM4E | |
| SCHEMBL23950211 | 0.77 | NLRP3 (0.55) | NLRP3POLBKDM4E | |
| SCHEMBL23950582 | 0.75 | KDM4E (0.41) | NLRP3POLBKDM4E | |
| SCHEMBL23950466 | 0.74 | NLRP3 (0.59) | NLRP3TP53PDE4BGPR139 | |
| SCHEMBL23950470 | 0.74 | KDM4E (0.40) | NLRP3POLBMAPTKDM4E | |
| SCHEMBL23950168 | 0.73 | KDM4E (0.39) | NLRP3POLBKDM4E | |
| SCHEMBL23950380 | 0.73 | POLB (0.44) | NLRP3TP53POLBRXFP1 | |
| SCHEMBL23950498 | 0.72 | NLRP3 (0.43) | NLRP3TP53PDE4BPOLBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | NLRP3 1/4885TP53 2445/4885PDE4B 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.